Top-cited gout literature tracks a shift from urate control to broader disease burden
A new bibliometric analysis of the 100 most-cited articles in gout maps how the field has evolved over more than two decades. The citation profile is concentrated in a small number of journals, institutions, and investigators, but the more important signal is conceptual: the literature has moved well beyond serum urate alone.
The most-cited paper in the dataset was published in 2006 and accumulated 4,359 citations, a scale that speaks to how intensely clinicians and researchers have tried to define gout as a systemic disease rather than a simple episodic arthritis. Across the 100 articles, publication venues were spread across 34 journals, with Annals of the Rheumatic Diseases contributing the largest share. The United States led country-level output, the University of Pennsylvania was the most productive institution, and Choi HK emerged as the most prolific author in the set.
One sentence captures the center of gravity in the field: gout research is no longer dominated by crystal biology alone.
Citation patterns point to a mature, clinically expanded research field
Bibliometric studies do more than count papers. They expose where a specialty has invested intellectual capital, and which questions have proven durable enough to keep earning citations. In gout, the most influential articles were not confined to one type of study design or one narrow clinical problem. Observational studies were the most common design among the top-cited papers, which is consistent with a disease that is deeply shaped by population risk factors, comorbid illness, medication exposure, and long-term outcomes.
That emphasis matters because gout is managed across multiple clinical contexts: acute flares, chronic hyperuricemia, recurrent joint disease, renal impairment, cardiovascular risk, and quality-of-life loss. The citation record suggests researchers have increasingly recognized that a person with gout is not just someone with episodic joint inflammation, but someone who may carry a broader burden of metabolic and vascular disease. The accumulation of citations around epidemiology and comorbidity reflects that shift in bedside thinking.
The data also show that the field is geographically and institutionally concentrated. A few countries and academic centers have supplied a large share of the most influential work, which often happens when one disease area matures into a sustained research program. In practical terms, this concentration can accelerate progress, but it can also narrow perspective if the research agenda becomes too dependent on a small number of networks or health systems.
Epidemiology, mechanisms, pain, and comorbidities dominate the keyword map
Keyword co-occurrence analysis grouped the top-cited literature into four major research domains: epidemiology, pathophysiological mechanisms, pain management, and comorbidities. Each domain reflects a different clinical layer of gout care. Epidemiology addresses who gets the disease and how often. Mechanistic work asks why monosodium urate crystal deposition becomes clinically apparent in some patients and not others. Pain management covers the acute symptom burden that drives urgent care visits and disability. Comorbidity research moves outward from the joint to the patient’s cardiovascular, metabolic, and renal risk profile.
Frequently occurring keywords included hyperuricemia, gout, management, risk, arthritis, uric acid, prevalence, coronary heart disease, quality of life, and febuxostat. The mix is revealing. It shows that the literature has not treated hyperuricemia as a static laboratory abnormality; instead, it has linked urate biology to outcomes that matter to patients and clinicians. Cardiovascular disease appears in the keyword set for a reason: gout rarely exists in isolation, and the overlap with coronary heart disease keeps pulling attention toward systemic risk assessment.
A second sentence stands out: the field has steadily moved from explaining gout to managing its consequences.
Hyperuricemia and urate-lowering therapy remain the core axis
Even as the literature broadens, hyperuricemia and urate-lowering therapy remain the backbone of gout research. That is unsurprising. Urate deposition defines the disease process, and long-term control still depends on lowering the biologic substrate that drives crystal formation. The prominence of febuxostat among high-frequency keywords shows how much attention has gone into pharmacologic strategies for chronic control, especially when clinicians are trying to balance efficacy, tolerability, and long-term adherence.
The bibliometric profile suggests that treatment research has not been isolated from broader clinical questions. A medication for urate lowering is not evaluated only by its ability to reduce serum urate. It is also judged in the context of flare frequency, chronic arthropathy, comorbid cardiovascular disease, and patient function. That layered approach explains why quality of life appears alongside pharmacologic and epidemiologic terms in the keyword network.
Emerging attention to gut microbiota signals a broader mechanistic turn
The appearance of gut microbiota as an emerging topic suggests that gout research is entering a more multidisciplinary phase. This is not a casual add-on to the field. Microbiome biology offers a plausible route into urate handling, inflammatory tone, metabolic regulation, and treatment response. For a disease long framed by crystal burden and serum urate thresholds, that kind of biologic expansion opens space for precision-oriented work.
The bibliometric shift toward multidisciplinary and precision approaches fits the current clinical reality of gout care. Patients present with recurrent flares, but they also bring renal disease, obesity, hypertension, cardiovascular risk, medication barriers, and diet-related concerns. A narrow urate-centric model can miss those overlapping drivers. Research momentum appears to be moving toward a more integrated model in which the joint, the kidney, the vasculature, and the microbiome are treated as linked parts of the same disease burden.
What the citation map still cannot answer
Bibliometric analysis can identify influence, but it cannot determine which ideas improved care at the bedside. High citation counts may reflect enduring clinical importance, methodological novelty, or simply broad visibility across rheumatology and internal medicine. The study also cannot resolve whether the field’s shift toward comorbidity and long-term outcomes has translated into better flare prevention, tighter urate control, or fewer cardiovascular events in routine practice.
Even so, the pattern is useful. It shows a specialty moving from a narrow biochemical frame toward a longer horizon that includes disease burden, chronic outcomes, and integrated management. For gout, that evolution is clinically consequential because patients do not experience the disease in isolated biochemical units. They experience pain, recurrence, treatment complexity, and the cumulative weight of associated metabolic and cardiovascular disease.
The remaining challenge is not simply to produce more citation-rich papers, but to connect the most influential questions to measurable gains in everyday gout care.